- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01750905
Safety Study of Chimeric Natriuretic Peptide(CD-NP) in Stable LVAD Patients
A Phase I, Randomized, Double-blind, Placebo-controlled, Crossover Study Evaluating The Safety, Hemodynamic And Neurohumoral Effects of a Novel Chimeric Peptide, CD-NP, in Patients With Left Ventricular Assist
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a double blind, placebo-controlled phase I trial of the safety and neurohumoral activity of CD-NP, in the treatment of heart failure with LVAD support. Subjects more than 3 months after LVAD implantation will be screened at outpatient clinic visit appointments lists and interested qualified subjects will be either confronted at a visit or sent a letter in the mail to be consented and offered participation in this trial. Once consent has been obtained, baseline values will be established at day 1 and subjects will be given subcutaneous injection of placebo or CD-NP and stay overnight on two different visits in the Clinical Research Unit (CRU). Participant's will receive both placebo and the CD-NP during the study, one per visit. A final follow-up visit for clinical assessment will be conducted over the phone at the end of the study.
Potential subjects who present to Mayo Clinic, Rochester, Minnesota for follow up clinical visit after LVAD implantation will be identified by the study coordinator. A $300 remuneration per subject will be involved to compensate for the inconvenience to the subject. A $500 reimbursement of gas mileage will be provided for those who travel.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic in Rochester
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Male and non-pregnant/post-menopausal female, ages 18-90, in end-stage Heart Failure (HF) with LVAD support who are stable in the healed stage after at least 3 months from the LVAD implant (Destination therapy only) (the post-menopausal state is defined as the absence of menses for ≥ 1 year and serum follicle-stimulating hormone ≥ 20 IU/L; sterilization in the female is defined as bilateral tubal occlusion for ≥ 6 months, bilateral oophorectomy, or complete hysterectomy)
- Be willing to provide informed consent.
Exclusion Criteria
- Known allergy or other adverse reactions to exogenous natriuretic peptides (CD-NP or its components, nesiritide, other natriuretic peptides, or related compounds).
- Women who are pregnant, or breast-feeding.
- Having received nesiritide within 7 days prior to prior to entry into the study.
- Having received any investigational drug or device within 30 days prior to entry into the study.
- Clinically unstable patients (e.g. mean blood pressure < 70 mmHg, ongoing requirement for vasopressors, or mechanical ventilation).
- Recent hospitalization for decompensated HF or recent defibrillation for cardiac resuscitation within 30 days prior to randomization.
- Patients with guarded prognosis who are unlikely to derive meaningful benefit from CD-NP.
- Use of sulfonamides, non-steroidal anti-inflammatory drugs, probenecid, or other drugs that are known to alter renal function within one week of the first dose of CD-NP or placebo.
- Presence of cardiac lesions or comorbidities that may contraindicate the use of natriuretic peptides, such as clinically significant cardiac valvular stenosis, hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, primary pulmonary hypertension, or uncorrected congenital heart disease that contraindicates the use of vasodilators.
- Symptomatic carotid artery disease, known critical carotid stenosis, or stroke within the past 3 months
- Clinically significant renal artery stenosis
- Baseline hemoglobin < 9.0 g/dl.
- Serum sodium < 130 mEq/L, potassium < 3.6 milliequivalents per Liter (mEq/L), or magnesium < 1.5 mEq/L.
- Elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) at least 5 times the upper limit of normal or bilirubin at least 5 times the upper limit of normal
- Creatinine clearance (CrCl) < 30 ml.min-1.1.73m-2, as calculated by Cockcroft-Gault formula(35) and adjusted for body surface area within 3 months or at screening, or requirement for dialysis.
- History of alcohol or drug abuse within the past 6 months.
- Inability to communicate effectively with study personnel.
- BMI >40
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: CD-NP
CD-NP 5 ug/kg subcutaneous injection (SQ)
|
CD-NP 5 ug/kg subcutaneous injection (SQ)
|
Placebo Comparator: Placebo
Placebo: Vehicle (D5W) SQ
|
Vehicle (D5W) SQ
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of subjects with Hypotension
Time Frame: approx day 9
|
approx day 9
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mean plasma Cyclic guanosine monophosphate (cGMP) level
Time Frame: Approx day 9
|
Approx day 9
|
Mean aldosterone level
Time Frame: approx 9 days
|
approx 9 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: John Schirger, MD, Mayo Clinic
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 12-001869
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Left Ventricular Insufficiency
-
Mayo ClinicAbbott Medical DevicesCompletedRight Ventricular Dysfunction | Left Ventricular Dysfunction | Tricuspid RegurgitationUnited States
-
Asan Medical CenterMerck Sharp & Dohme LLCCompletedMitral Valve Insufficiency | Left Ventricular Systolic DysfunctionKorea, Republic of
-
University Hospital, Clermont-FerrandCompletedSevere Mitral Regurgitation | Preserved Ventricular Ejection FractionFrance
-
Asan Medical CenterNovartisCompletedMitral Valve Insufficiency | Left Ventricular DysfunctionKorea, Republic of
-
MyocorCompletedHeart Failure | Mitral Valve Regurgitation | Left Ventricular DysfunctionUnited States
-
University of LeipzigCompletedLeft Ventricular Hypertrophy | Left Ventricular Failure | Left Ventricular Non-compaction CardiomyopathyGermany
-
Lawson Health Research InstituteMedtronicTerminatedHeart Failure, Left Ventricular DysfunctionCanada
-
AstraZenecaCompletedLeft Ventricle FunctionSweden
-
Lawson Health Research InstituteRecruiting
-
Assistance Publique Hopitaux De MarseilleCompletedLeft Ventricular Non CompactionFrance
Clinical Trials on CD-NP
-
Nile TherapeuticsCompletedAcute Decompensated Heart FailureUnited States, Germany, Israel
-
Nile TherapeuticsCompleted
-
Mayo ClinicCompletedST Elevation (STEMI) Myocardial Infarction of Anterior WallUnited States
-
Mayo ClinicCompletedStable Chronic Heart FailureUnited States
-
Nile TherapeuticsIntegriumCompletedHeart Failure | Chronic Heart Failure | CHF | ADHFUnited States
-
Nile TherapeuticsMomentum Research, Inc.CompletedAcute Decompensated Heart FailureRussian Federation
-
Mayo ClinicWithdrawnHeart Failure | Left Ventricular Assist Device | Natriuretic Peptide
-
John A. SchirgerNational Institutes of Health (NIH)WithdrawnHeart Failure | Renal Insufficiency
-
Philip Morris Products S.A.Completed